Record profits for Hikma pharmaceuticals

Hikma pharmaceuticals announced this week its first-half share results, which far exceeded market expectations. In addition, share prices have increased over 46% this year.

The first half results announced this week showed 20% revenue growth and 156% increase in adjusted EPS.

The fast-growing multinational pharmaceutical group focuses on the manufacturing, marketing and sales of generic drugs.

"The Group has made an excellent start to this year and all of our businesses are performing well... Overall, the Group is performing well and I am very pleased to be able to raise our Group guidance to around 20% revenue growth for the full year."

Said Darwazah, Chief Executive Officer of Hikma

The company is benefitting, in particular, from strong demand for its products in the US and new product launches.